Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0043
Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 1
Paediatric Committee (PDCO): 23-26 July 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 July 2024 to 26 July 2024
Agenda - PDCO agenda of the 23-26 July 2024 meeting
ACT EU consolidated advice pilots: information and training webinar for Applicants, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 July 2024, 15:00 (CEST) to 17 July 2024, 17:00 (CEST)
Orphan designation: 4-(4-Methyl-piperazin-1-yl)-N-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1H-indazol-3-yl}-benzamide hemioxalate Treatment of acute myeloid leukaemia, 21/03/2024 Positive
Orphan designation: Mibavademab Treatment of Lawrence syndrome, 21/03/2024 Positive
Orphan designation: Sevasemten Treatment of Becker muscular dystrophy, 21/03/2024 Positive
Orphan designation: zatolmilast Treatment of fragile X syndrome, 21/03/2024 Positive
Orphan designation: Mibavademab Treatment of Berardinelli-Seip syndrome (congenital generalised lipodystrophy), 21/03/2024 Positive